Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine
Fen Fen Li,Ka Wai Kam,Yuzhou Zhang,Shu Min Tang,Alvin L Young,Li Jia Chen,Clement C Tham,Chi Pui Pang,Jason C Yam,Alvin L. Young,Clement C. Tham,Jason C. Yam
DOI: https://doi.org/10.1016/j.ophtha.2020.06.004
IF: 14.277
2020-12-01
Ophthalmology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Anti-myopia effect of 0.01% atropine over placebo affected spherical equivalent (SE) but not axial length (AL) elongation in both ATOM2 study and LAMP study. It is possible that atropine might exert its effect through changes in corneal properties or lens power.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>To evaluate changes of ocular biometrics in the 0.05%, 0.025%, and 0.01% atropine groups compared to placebo over one year based on the LAMP study.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Design</h3><p>Double-blinded, randomized, placebo-controlled trial.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Participants</h3><p>383 children aged 4 to 12 years, who were randomly assigned to receive 0.05%, 0.025%, 0.01% atropine, or placebo once daily in both eyes and completed the first year of the LAMP study.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Cycloplegic SE, AL, corneal curvatures, and anterior chamber depth (ACD), were measured by IOL Master. Corneal astigmatism and lens power were calculated. The ocular biometric parameters changes were compared among various groups. Contributions to SE progression from ocular parameters were determined and compared among various groups.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main outcome measures</h3><p>Changes in ocular biometrics and their associations with the changes in SE.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Over one year, changes in AL were 0.20±0.25mm, 0.29±0.20mm, 0.36±0.29mm, and 0.41±0.22mm in 0.05%, 0.025%, 0.01% atropine and placebo, respectively (p<0.001), with a concentration-dependent response. Corneal power remained stable, and its changes were similar across all atropine concentrations, with -0.02±0.14D, -0.01±0.14D, -0.01±0.12D, and 0.01±0.14D in 0.05%, 0.025%, and 0.01% atropine, and placebo, respectively (p = 0.10). Lens power decreased over time in each concentration, but its changes were also similar across all concentrations, with -0.31±0.43D, -0.38±0.47D, -0.40±0.43D, and -0.41±0.43D in 0.05%, 0.025%, 0.01% atropine and placebo respectively (p=0.24). ACD deepened over time, but its changes remained similar across all concentrations (p=0.41). The contributions to SE progression from the ocular biometric changes including changes of K, AL, and lens power after adjusting for age and gender, in each concentration were similar (p>0.05).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Low-concentrations of atropine 0.05%, 0.025%, and 0.01% have no clinical effect on corneal power and lens power. The anti-myopic effects of low-concentration atropine act mainly on reducing AL elongation, and therefore could reduce risk of subsequent myopia complications.</p>
ophthalmology